MED — Medifast Income Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesAdventurousSmall CapSuper Stock

Annual income statement for Medifast, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	935	1,526	1,599	1,072	602
Cost of Revenue
Gross Profit	698	1,128	1,140	776	445
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	801	1,310	1,414	946	600
Operating Profit	134	216	185	126	2.88
Total Net Non Operating Interest Income / Expense
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	134	216	184	129	3.79
Provision for Income Taxes
Net Income After Taxes	103	164	144	99.4	2.09
Net Income Before Extraordinary Items
Net Income	103	164	144	99.4	2.09
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	103	164	144	99.4	2.09
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	9.14	13.9	12.7	9.1	0.82
Dividends per Share